184 related articles for article (PubMed ID: 36650455)
1. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Sharma A; Ranvir R; Kadam S; Ingale K; Patel H; Nyska A; Jain MR
BMC Cancer; 2023 Jan; 23(1):59. PubMed ID: 36650455
[TBL] [Abstract][Full Text] [Related]
2. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
4. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
Kishida N; Matsuda S; Itano O; Shinoda M; Kitago M; Yagi H; Abe Y; Hibi T; Masugi Y; Aiura K; Sakamoto M; Kitagawa Y
BMC Gastroenterol; 2016 Jun; 16(1):61. PubMed ID: 27296438
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Li S; Ghoshal S; Sojoodi M; Arora G; Masia R; Erstad DJ; Lanuti M; Hoshida Y; Baumert TF; Tanabe KK; Fuchs BC
J Gastrointest Surg; 2019 Jan; 23(1):101-111. PubMed ID: 30367397
[TBL] [Abstract][Full Text] [Related]
7. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
8. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid.
Lau HC; Zhang X; Ji F; Lin Y; Liang W; Li Q; Chen D; Fong W; Kang X; Liu W; Chu ES; Ng QW; Yu J
EBioMedicine; 2024 Feb; 100():104952. PubMed ID: 38176203
[TBL] [Abstract][Full Text] [Related]
9. Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
Haberl EM; Pohl R; Rein-Fischboeck L; Höring M; Krautbauer S; Liebisch G; Buechler C
Lipids Health Dis; 2020 Dec; 19(1):250. PubMed ID: 33298075
[TBL] [Abstract][Full Text] [Related]
10. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
13. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
[TBL] [Abstract][Full Text] [Related]
14. miR-21-5p promotes NASH-related hepatocarcinogenesis.
Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
[TBL] [Abstract][Full Text] [Related]
15. Reduced Serum Cholesterol and Triglyceride Levels in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet (CDAHFD)-Induced Mouse Model of Non-alcoholic Steatohepatitis (NASH).
Yasuda D; Torii H; Shimizu R; Hiraoka Y; Kume N
Biol Pharm Bull; 2020; 43(4):616-618. PubMed ID: 32238704
[TBL] [Abstract][Full Text] [Related]
16. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
17. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in diet-induced steatotic disease in Cyp2b-null mice.
Heintz MM; McRee R; Kumar R; Baldwin WS
PLoS One; 2020; 15(3):e0229896. PubMed ID: 32155178
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
[TBL] [Abstract][Full Text] [Related]
20. Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet.
Dungubat E; Watabe S; Togashi-Kumagai A; Watanabe M; Kobayashi Y; Harada N; Yamaji R; Fukusato T; Lodon G; Sevjid B; Takahashi Y
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33353230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
